Patents by Inventor Peter Ordentlich

Peter Ordentlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230165858
    Abstract: The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 7, 2021
    Publication date: June 1, 2023
    Inventors: Gerard M. MCGEEHAN, Peter ORDENTLICH, Galit ROSEN, Steven A. SMITH
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20230061048
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Application
    Filed: March 29, 2022
    Publication date: March 2, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventor: Peter ORDENTLICH
  • ANTIBODIES FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
    Publication number: 20230035183
    Abstract: The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab.
    Type: Application
    Filed: December 9, 2020
    Publication date: February 2, 2023
    Inventors: Peter ORDENTLICH, Michael MEYERS, Briggs W. MORRISON
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20230022573
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: April 8, 2022
    Publication date: January 26, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • Selection of patients for combination therapy
    Patent number: 11397184
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 26, 2022
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventor: Peter Ordentlich
  • Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
    Patent number: 11324822
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 10, 2022
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Robert Goodenow, Peter Ordentlich
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20210239697
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 5, 2021
    Inventors: Peter ORDENTLICH, Lei WANG, Serap SANKOH, Michael MEYERS
  • COMBINATION THERAPIES
    Publication number: 20200171150
    Abstract: The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 4, 2020
    Inventors: Peter ORDENTLICH, Lei WANG
  • METHODS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20190343844
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Application
    Filed: January 15, 2019
    Publication date: November 14, 2019
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF OVARIAN CANCER
    Publication number: 20190290759
    Abstract: Described herein are methods for the treatment of heavily pre-treated recurrent ovarian cancer. In particular, methods are provided for the treatment of heavily pre-treated recurrent ovarian cancer with a combination of entinostat and an anti-PD-L1 antibody.
    Type: Application
    Filed: December 28, 2016
    Publication date: September 26, 2019
    Inventors: Peter Ordentlich, Michael Meyers
  • Methods for the treatment of breast cancer
    Patent number: 10226472
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 12, 2019
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Robert Goodenow, Peter Ordentlich
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20180353602
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of metastatic triple negative breast cancer with a combination of entinostat and an anti-PD-L1 antibody, such as MPDL3280A.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 13, 2018
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • SELECTION OF PATIENTS FOR COMBINATION THERAPY
    Publication number: 20180252721
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Application
    Filed: September 2, 2016
    Publication date: September 6, 2018
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventor: Peter Ordentlich
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20180078639
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 22, 2018
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • METHODS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20140378420
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 25, 2014
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Robert Goodenow, Peter Ordentlich
  • ADMINISTRATION OF AN INHIBITOR OF HDAC
    Publication number: 20130303575
    Abstract: Methods of treating patients with SNDX-275 are provided.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 14, 2013
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Konrad BURKE, Peter ORDENTLICH, Robert S. Goodenow
  • Substituted pyrimidine compositions and methods of use
    Patent number: 8455489
    Abstract: Novel compositions and methods of using substituted pyrimidines which have the general formula: (I).
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: June 4, 2013
    Assignee: Exelixis, Inc.
    Inventors: Richard Martin, Raju Mohan, Peter Ordentlich
  • Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
    Publication number: 20110182888
    Abstract: Methods of treating patients with an HDAC inhibitor and a HER-2 inhibitor are provided herein. In some embodiments, a SERM is also administered.
    Type: Application
    Filed: April 7, 2009
    Publication date: July 28, 2011
    Inventors: Peter Ordentlich, Bob Goodenow, Bolin Liu, Xiaoping Huang
  • Administration of an Inhibitor of HDAC
    Publication number: 20100305167
    Abstract: Methods of treating patients with SNDX-275 are provided.
    Type: Application
    Filed: November 19, 2008
    Publication date: December 2, 2010
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Konrad Burk, Peter Ordentlich, Robert Goodenow
  • Novel Compounds and Methods of Using Them
    Publication number: 20100298270
    Abstract: Described herein are novel HDAC modulators, formulations containing them and methods of using them. In some embodiments, the HDAC modulators possess specific stereo chemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.
    Type: Application
    Filed: July 23, 2008
    Publication date: November 25, 2010
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: John F.W. Keana, Peter Ordentlich, Robert Goodenow